Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review
Background Oral corticosteroid use increases the risk of systemic adverse effects including osteoporosis, bone fractures, diabetes, ocular disorders and respiratory infections. We sought to understand if inhaled corticosteroid (ICS) use in asthma is also associated with increased risk of systemic ef...
Saved in:
| Main Authors: | Chris Griffiths, Chloe I Bloom, Roshni Patel, Sumrah A Naqvi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-09-01
|
| Series: | BMJ Open Respiratory Research |
| Online Access: | https://bmjopenrespres.bmj.com/content/7/1/e000756.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhaled Corticosteroid Therapy Does Not Control Asthma
by: Robert L Cowie, et al.
Published: (2004-01-01) -
Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial)
by: J Mark FitzGerald, et al.
Published: (2009-01-01) -
Association of Corticosteroid Inhaler Type with Saliva Microbiome in Moderate-to-Severe Pediatric Asthma
by: Amir Hossein Alizadeh Bahmani, et al.
Published: (2025-01-01) -
Montelukast as Add-On Therapy with Inhaled Corticosteroids or Inhaled Corticosteroids and Long-Acting Beta-2-Agonists in the Management of Patients Diagnosed with Asthma and Concurrent Allergic Rhinitis (The RADAR Trial)
by: Paul K Keith, et al.
Published: (2009-01-01) -
Minimising inhaled corticosteroids for COPD
by: Benji Heran, et al.
Published: (2024-12-01)